References
- Prati F, Mastroianni F, Paoletti G, Marco V, Biccirè FG, Gatto L. Seeking and treating inflammation in ischaemic heart disease: Are we ready? Eur Heart J Suppl 2025; 27(Suppl 3):iii122–iii25.
- Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45(36):3415–3537.
- Liuzzo G, Patrono C. Weekly Journal Scan: Platelet thromboxane suppression as the mechanism of the anti-metastatic effect of aspirin. Eur Heart J 2025;46:2356–2358.
- Bay B, Tanner R, Gao M, Oliva A, Sartori S, Vogel B, Gitto M, Smith KF, Di Muro FM, Hooda A. Residual cholesterol and inflammatory risk in statintreated patients undergoing percutaneous coronary intervention. Eur Heart J 2025;46(32):3167–3177.
- Cai X, White Q, Johnson WC, Hansen SL, Dardari ZA, Blaha M, Michos ED, Lima JAC, deFilippi CR, Budoff MJ, Watson KE, McClelland RL, Yang EH. Baseline cardiac biomarker levels as predictors of cancer risk in the MESA cohort. JACC Adv 2025;4(7):101884.
- Farukhi ZM, Mora S. Lipoprotein(a) association with residual risk: what has inflammation got to do with it? Eur Heart J 2024;45(12):1055–1057.
- Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, et al. Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health 2023;20(18):6721. doi:10.3390/ijerph20186721.
- Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43(39):3925– 3946.
- Schmidt LE, Speidl WS, Tsimikas S, Mayr M. Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics. Eur Heart J 2023;44(27):2420–2422.
- Libby P, Pasterkamp G. Requiem for the ‘vulnerable plaque’. Eur Heart J 2015;36(43):2984–2987.
- Nurmohamed NS, Kraaijenhof JM, Mayr M, Nicholls SJ, Koenig W, Catapano AL, Stroes ESG. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J 2023;44(18):1594–1607.
- Müller FS, Aherrahrou Z, Grasshoff H, Heidorn MW, Humrich JY, Johanson L, Aherrahrou R, Reinberger T, Schulz A, ten Cate V, et al. Autoantibodies against the chemokine receptor 3 predict cardiovascular risk. Eur Heart J 2023;44(47):4935–4949.
- Sánchez-Cabo F, Fuster V, Silla-Castro JC, González G, Lorenzo Vivas E, Alvarez R, Callejas S, Benguría A, Gil E, Núñez E, et al. Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study. Eur Heart J 2023;44(29):2698–2709.
- Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J. Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. Eur Heart J 2024; doi:10.1093/ehjqcco/qcae099.
- Nidorf SM, Ben-Chetrit E, Ridker PM. Low-dose colchicine for atherosclerosis: long-term safety. Eur Heart J 2024;45(18):1596–1601.
- Kosmas CE, Bousvarou MD, Guzman E. Insulin resistance and cardiovascular disease. SAGE Journals 2023; first published online Mar 30, 2023.
- Pedicino D, Volpe M. Weekly Journal Scan: a large observational study unravels the wide-ranging effects of glucagonlike peptide-1 receptor agonists. Eur Heart J 2025;46:2713–2715.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389(24):2221–2232.
- Gurevitz C, Bajaj A, Khera AV, Do R, Schunkert H, Musunuru K, Rosenson RS. Gene therapy and genome editing for lipoprotein disorders. Eur Heart J 2025;00:1–14.